Key Takeaways
- • Four health tech companies closed $291 million in aggregate funding during August 2026, signaling sustained institutional investor appetite for AI-driven healthcare solutions and home-based care delivery models.
- • Cityblock Health raised $116 million in Series E funding to acquire Homeward Health and expand its AI-powered platform serving Medicaid and dual-eligible populations across clinical, behavioral, and social care domains.
- • Happy Health secured $75 million from ARCH Venture Partners and OpenLoop to accelerate clinical validation of its FDA-cleared smart ring for obstructive sleep apnea diagnosis and expand into additional health monitoring categories.
- • Flagler Health closed a $50 million Series B round led by Bessemer Venture Partners to scale its AI-native operating system for musculoskeletal care across the United States, bringing total capital raised to $63 million.
- • Network Bio launched with $50 million in financing from Section 32, Thiel Bio, and Founders Fund to develop disease-specific AI models leveraging the world's largest patient tissue training dataset for diagnostics and drug development acceleration.
Summary
August 2026 witnessed substantial capital deployment across the health technology sector, with four companies announcing significant funding rounds totaling $291 million. The funding activity reflects a concentrated institutional focus on AI-powered healthcare infrastructure, particularly in underserved care delivery models and diagnostic innovation.
Cityblock Health, the New York City-based primary care platform, raised $116 million in Series E funding to support its acquisition of Homeward Health, a rural healthcare provider. The company operates an AI-powered system that aggregates physical, behavioral, and social health data to deliver predictive insights across care teams. Cityblock primarily serves Medicaid and dual-eligible populations through in-home clinical care, virtual services, and community-based clinics. The Series E proceeds will fund platform optimization, operational enhancements, care model refinement, and technology and data infrastructure expansion.
Happy Health secured $75 million in funding from venture investors ARCH Venture Partners and OpenLoop for its FDA-cleared smart ring technology designed for at-home obstructive sleep apnea diagnosis. The platform uses continuous health data and AI algorithms to establish personalized baselines for individual patients, enabling clinicians to identify meaningful health changes. The capital will accelerate clinical validation of the company's technology while building infrastructure to expand beyond sleep health into additional diagnostic categories.
Flagler Health, an AI-native operating system for musculoskeletal care based in New York City, closed a $50 million Series B round led by Bessemer Venture Partners with participation from SignalFire, Alumni Ventures, Streamlined, 186 Ventures, Proof VC, Tribeca Venture Partners, and Offscript. The company operates across 36 states and supports thousands of MSK providers. The funding brings Flagler Health's total capital raised to $63 million and will support nationwide scaling efforts.
Network Bio, a Palo Alto-based biotechnology company, launched with $50 million in financing from Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund, and JSL Health Capital. The company develops disease-specific AI models trained on human biological data and collaborates with academic medical centers to accelerate diagnostics, biomarker discovery, and drug development. Network Bio claims access to the world's largest patient tissue training dataset for its platform expansion.
Cityblock Health, the New York City-based primary care platform, raised $116 million in Series E funding to support its acquisition of Homeward Health, a rural healthcare provider. The company operates an AI-powered system that aggregates physical, behavioral, and social health data to deliver predictive insights across care teams. Cityblock primarily serves Medicaid and dual-eligible populations through in-home clinical care, virtual services, and community-based clinics. The Series E proceeds will fund platform optimization, operational enhancements, care model refinement, and technology and data infrastructure expansion.
Happy Health secured $75 million in funding from venture investors ARCH Venture Partners and OpenLoop for its FDA-cleared smart ring technology designed for at-home obstructive sleep apnea diagnosis. The platform uses continuous health data and AI algorithms to establish personalized baselines for individual patients, enabling clinicians to identify meaningful health changes. The capital will accelerate clinical validation of the company's technology while building infrastructure to expand beyond sleep health into additional diagnostic categories.
Flagler Health, an AI-native operating system for musculoskeletal care based in New York City, closed a $50 million Series B round led by Bessemer Venture Partners with participation from SignalFire, Alumni Ventures, Streamlined, 186 Ventures, Proof VC, Tribeca Venture Partners, and Offscript. The company operates across 36 states and supports thousands of MSK providers. The funding brings Flagler Health's total capital raised to $63 million and will support nationwide scaling efforts.
Network Bio, a Palo Alto-based biotechnology company, launched with $50 million in financing from Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund, and JSL Health Capital. The company develops disease-specific AI models trained on human biological data and collaborates with academic medical centers to accelerate diagnostics, biomarker discovery, and drug development. Network Bio claims access to the world's largest patient tissue training dataset for its platform expansion.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.